safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-65Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESСовременные подходы к сбору и репортированию информации о побочном действии лекарственных средствModern approaches to collecting and reporting information on side effectsЗатолочинаК. Э.ZatolochinaK. E.noemail@neicon.ruСнегиреваИ. И.SnegirevaI. I.noemail@neicon.ruКазаковА. С.KazakovA. S.noemail@neicon.ruКолесниковаЕ. Ю.KolesnikovaE. Yu.noemail@neicon.ruЖуравлеваЕ. О.ZhuravlevaE. O.noemail@neicon.ruБукатинаТ. М.BukatinaT. M.noemail@neicon.ruДармостуковаМ. А.DarmostukovaM. A.noemail@neicon.ruНаучный центр экспертизы средств медицинского примененияРоссияScientific Centre for Expert Evaluation of Medicinal ProductsRussian Federation201720022018513238Copyright © Затолочина К.Э., Снегирева И.И., Казаков А.С., Колесникова Е.Ю., Журавлева Е.О., Букатина Т.М., Дармостукова М.А., 20182018Затолочина К.Э., Снегирева И.И., Казаков А.С., Колесникова Е.Ю., Журавлева Е.О., Букатина Т.М., Дармостукова М.А.Zatolochina K.E., Snegireva I.I., Kazakov A.S., Kolesnikova E.Y., Zhuravleva E.O., Bukatina T.M., Darmostukova M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/65

В обзоре представлены результаты анализа отечественной и зарубежной научной литературы по вопросам выявления и репортирования информации о побочном действии лекарственных средств для систем мониторинга безопасности лекарственных средств. Рассмотрены элементы системы сбора информации о нежелательных реакциях на лекарственные средства, а также вопросы технического усовершенствования способов выявления и репортирования сведений и вопросы расширения числа лиц участвующих в репортировании и поиска новых источников данных о безопасности лекарственных средств. Отмечена роль пациентов в качестве источников и репортеров информации, рассмотрена возможность использования социальных медийных средств как источников новых данных о побочном действии лекарственных препаратов.

We have prepared this review of the domestic and foreign scientific literature to characterize the different modern approaches to collecting of ADR information. Advent of new technologies in mobile devices and software applications is leading to facilitate information gathering. The importance of medical literature, social media and patient-generated data for pharmacovigilance were highlighted.

фармаконадзорспонтанные сообщениянежелательная реакцияpharmacovigilancespontaneous reportsadverse drug reactionReferencesStrom BL. Pharmacoepidemiology. Oxford: Wiley-Blackwell; 2012.Strom B. L. Pharmacoepidemiology. Oxford: Wiley-Blackwell; 2012.Руководство по экспертизе лекарственных средств. Том III. М.: ПОЛИГРАФ-ПЛЮС; 2014.Guidelines for the examination of drugs. V. III. Mjscow: POLYGRAPH PLUS; 2014 (in Russian).Меркулов ВА, Бунятян НД, Сакаева ИВ, Лепахин ВК, Романов БК, Ефремова ТА. Новые законодательные инициативы по повышению безопасности лекарственных средств в европейском союзе. Ведомости Научного центра экспертизы средств медицинского применения 2013; 3: 45-48.Merkulov VA, Bunyatyan ND, Sakaeva IV, Lepakhin VC, Romanov BK. New legislative initiatives for improving the safety of medicines in the European Union. The Bulletin of the Scientific center for expert evaluation of medical products 2013; 3: 45–48 (in Russian).Снегирева ИИ, Затолочина КЭ, Озерецковский НА, Романов БК, Миронов АН. Фармаконадзор вакцин в России: нормативно-правовое регулирование, особенности развития на современном этапе. Ведомости Научного центра экспертизы средств медицинского применения 2014; 4: 27-31.Snegireva II, Zatolochina KE, Ozeretskovsky NA, Romanov BK, Mironov AN. Vaccine pharmacovigilance in Russia, legal and regulatory framework, current stage of development. The Bulletin of the Scientific center for expert evaluation of medical products 2014; 4: 27–31. (in Russian)Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013; 36(2): 75-81. doi: 10.1007/s40264-012-0014-6.Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013; 36(2): 75–81. doi: 10.1007/s40264-012-0014-6.Härmark L, Raine J, Leufkens H, Edwards R, et al. Patient-Reported Safety Information: A Renaissance of Pharmacovigilance? Drug Saf. 2016; 39(10): 883-90. doi: 10.1007/s40264-016-0441-x.Härmark L, Raine J, Leufkens H, Edwards R, et al. Patient-Reported Safety Information: A Renaissance of Pharmacovigilance? Drug Saf. 2016; 39(10): 883–90. doi: 10.1007/s40264-016-0441-x.Directive 2010/84/EU. Offcial Journal of the European Union 2010; L. 348-74-99.Directive 2010/84/EU. Offcial Journal of the European Union 2010; L. 348-74-99.Regulation 1235/2010. Offcial Journal of the European Union 2010; L. 348-1-16.Regulation 1235/2010. Offcial Journal of the European Union 2010; L. 348-1-16.van Hunsel F, Talsma A, van Puijenbroek E, de Jong-van den Berg L, van Grootheest K. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf. 2011; 20: 286-91.van Hunsel F, Talsma A, van Puijenbroek E, de Jong-van den Berg L, van Grootheest K. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf. 2011; 20:286–91.Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK’s Yellow Card Scheme. Drug Saf. 2013; 36: 199-206.Hazell L, Cornelius V, Hannaford P, Shakir S, Avery AJ. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of dverse drug reactions in the UK’s Yellow Card Scheme. Drug Saf. 2013; 36: 199–206.Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63:148-56.Blenkinsopp A,Wilkie P,Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007; 63: 148–56.Medawar C, Herxheimer A. A comparision of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behavior with paroxetine. Int J Risk Saf Med. 2004; 16: 5-19.Medawar C, Herxheimer A. A comparision of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behavior with paroxetine. Int J Risk Saf Med. 2004; 16: 5–19.Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol. Assess. 2011; 15:1 - iv.Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol. Assess. 2011; 15:1 – iv.Rolfes L, van Hunsel F, Wilkes S, van Grootheest K, van Puijenbroek E. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information. Pharmacoepidemiol Drug Saf. 2015; 24: 152-8.Rolfes L, van Hunsel F, Wilkes S, van Grootheest K, van Puijenbroek E. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information. Pharmacoepidemiol Drug Saf. 2015; 24: 152–8.de Langen J, van Hunsel F, Passier A, deJong-van den BergL, van Grootheest K. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008; 31: 515-24.de Langen J, van Hunsel F, Passier A, deJong-van den BergL, van Grootheest K. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008; 31: 515–24.Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009; 29: 157-64.Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009; 29: 157–64.Ekhart CG, van Puijenbroek EP. Does sexual dysfunction persist upon discontinuation of selective serotonin reuptake inhibitors? Tijdschr Psychiatr. 2014; 56: 336-40.Ekhart CG, van Puijenbroek EP. Does sexual dysfunction persist upon discontinuation of selective serotonin reuptake inhibitors? Tijdschr Psychiatr. 2014; 56: 336–40.Netherlands Pharmacovigilance Centre Lareb. SSRIs and aggression. [Электронный ресурс] 2016 (дата обращения 21.01.2017). Доступно на: http://www.lareb.nl/Signalen/kwb_2009_3_ssris.Netherlands Pharmacovigilance Centre Lareb. SSRIs and aggression. [Electronic source] 2016 (cited 21 Dec 2017). Avaible at: http://www.lareb.nl/Signalen/kwb_2009_3_ssris.Netherlands Pharmacovigilance Centre Lareb. SSRI’s and aggression an update. [Электронный ресурс] 2014 (дата обращения 21.01.2017). Доступно на: http://www.lareb.nl/Signalen/KWB_2014_2_SSRI.Netherlands Pharmacovigilance Centre Lareb. SSRI’s and aggression an update. [Electronic source] 2014 (cited 21 Dec 2017). Avaible at http://www.lareb.nl/Signalen/KWB_2014_2_SSRI.de Graaf L, van Puijenbroek EP. Serotonin reuptake inhibitors and shocklike paresthesia. J Clin Psychiatry. 2003; 64: 969-71.de Graaf L, van Puijenbroek EP. Serotonin reuptake inhibitors and shocklike paresthesia. J Clin Psychiatry. 2003; 64: 969–71.Frost L, Lal S. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am J Psychiatry. 1995; 152: 810.Frost L, Lal S. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am J Psychiatry. 1995; 152: 810.Netherlands Pharmacovigilance Centre Lareb. Serotonin re-uptake inhibitors (SSRIs) and Shocklike Paraesthesia. [Электронный ресурс] 2002 (дата обращения 21.01.2017). Доступно на: http://www.lareb.nl/Signalen/kwb_2002_2_ssris. Accessed 21 Jan 2016.Netherlands Pharmacovigilance Centre Lareb. Serotonin re-uptake inhibitors (SSRIs) and Shocklike Paraesthesia. [Electronic source] 2002 (cited 21 Dec 2017). Avaible at http://www.lareb.nl/Signalen/kwb_2002_2_ssris. Accessed 21 Jan 2016.Netherlands Pharmacovigilance Centre Lareb. Duloxetine and Electric Shock Sensations. [Электронный ресурс] 2011 (дата обращения 21.01.2017). Доступно на: http://www.lareb.nl/Signalen/kwb_2011_2_dulox.Netherlands Pharmacovigilance Centre Lareb. Duloxetine and Electric Shock Sensations[Electronic source] 2011 (cited 21 Dec 2017). Avaible at http://www.lareb.nl/Signalen/kwb_2011_2_dulox.Van Hunsel F. Examples of the role of patient reports in safety signals. Lareb 2015.Van Hunsel F. Examples of the role of patient reports in safety signals. Lareb 2015.Download the Yellow Card mobile app to report suspected adverse drug reactions. [Электронный ресурс] 2015 (дата обращения 21.01.2017). Доступно на: https://www.gov.uk/drug-safety-update/.Download the Yellow Card mobile app to report suspected adverse drug reactions. [Electronic source] 2002 (cited 21 Dec 2017). Avaible at https://www.gov.uk/drug-safety-update.WEB-RADR. IMI - Innovative Medicines Initiative. [Электронный ресурс] 2014 (дата обращения 10.01.2017). Доступно на: https://www.imi.europa.eu/content/web-radr.WEB-RADR. IMI — Innovative Medicines Initiative. [Electronic source] 2002 (cited 21 Dec 2017). Avaible at https://www.imi.europa.eu/content/web-radr.Guideline on good pharmacovigilance practices (GVP) - Module VI (Rev 1) EMA/873138/2011 Rev 1. 2014.Guideline on good pharmacovigilance practices (GVP) — Module VI (Rev 1) EMA/873138/2011 Rev 1. 2014.Решение Совета Евразийской экономической комиссии от 03.11.2016 № 87 «Об утверждении Правил надлежащей практики фармаконадзора Евразийского экономического союза». [Электронный ресурс] 2015 (дата обращения 10.01.2017). Доступно на: https://docs.eaeunion.org/docs/ru-ru/01411948/cncd_21112016_87.Decision of the Council of the Eurasian Economic Commission dated 03.11.2016¹ 87 «On approval of rules of the Good Pharmacovigilance Practice of the Eurasian Economic Union». [Electronic source] 2016 (cited 21 Dec 2017). Avaible at https://docs.eaeunion.org/docs/ru-ru/01411948/cncd_21112016_87.Sarker A, Ginn R, Nikfarjam A, O’Connor K, Smith K, Jayaraman S, Upadhaya T, Gonzalez G. Utilizing social media data for pharmacovigilance: A review. J Biomed Inform. 2015; 54: 202-12. doi: 10.1016/j.jbi.2015.02.004. Epub 2015 Feb 23.Sarker A, Ginn R, Nikfarjam A, O’Connor K, Smith K, Jayaraman S, Upadhaya T, Gonzalez G. Utilizing social media data for pharmacovigilance: A review. J Biomed Inform. 2015; 54: 202–12. doi: 10.1016/j.jbi.2015.02.004. Epub 2015 Feb 23.Sloane R, Osanlou O, Lewis D, Bollegala D, Maskell S, Pirmohamed M. Social media and pharmacovigilance: A review of the opportunities and challenges. Br J Clin Pharmacol. 2015; 80(4): 910-20. doi: 10.1111/bcp. 12717. Epub 2015 Sep 2.Sloane R, Osanlou O, Lewis D, Bollegala D, Maskell S, Pirmohamed M. Social media and pharmacovigilance: A review of the opportunities and challenges. Br J Clin Pharmacol. 2015;80 (4): 910–20. doi: 10.1111/bcp. 12717. Epub 2015 Sep 2.Edwards R, Lindquist M. Social media and networks in pharmacovigilance: boon or bane? Drug Saf. 2011; 34(4): 267-71. doi: 10.2165/11590720-000000000-00000.Edwards R, Lindquist M. Social media and networks in pharmacovigilance: boon or bane? Drug Saf. 2011; 34(4): 267–71. doi: 10.2165/11590720-000000000-00000.Benton A, Ungar L, Hill S, Hennessy S, Mao J, Chung A, Leonard CE, Holmes JH. Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. J Biomed Inform. 2011; 44(6): 989-96.Benton A, Ungar L, Hill S, Hennessy S, Mao J, Chung A, Leonard CE, Holmes JH. Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. J Biomed Inform. 2011; 44(6): 989–96.Statista - The Statistics Portal for Market Data, Market Research and Market Studies. [Электронный ресурс] 2017 (дата обращения 10.01.2017). Доступно на: https://www.statista.com.Statista — The Statistics Portal for Market Data, Market Research and Market Studies. [Electronic source] 2002 (cited 21 Dec 2017). Avaible at https://www.statista.com.Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012; 91(6): 1010-21.Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012; 91(6): 1010–21.Kass-Hout TA, Alhinnawi H. Social media in public health. Br Med Bull. 2013; 108: 5-24.Kass-Hout TA, Alhinnawi H. Social media in public health. Br Med Bull. 2013; 108: 5–24.Harpaz R, Callahan A, Tamang S, Low Y, Odgers D, Finlayson S, Jung K, LePendu P, Shah NH. Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf. 2014; 37(10): 777-90.Harpaz R, Callahan A, Tamang S, Low Y, Odgers D, Finlayson S, Jung K, LePendu P, Shah NH. Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf. 2014; 37(10): 777–90.Lardon J, Abdellaoui R, Bellet F, Asfari H, Souvignet J, Texier N, Jaulent MC, Beyens MN, Burgun A, Bousquet C. Adverse Drug Reaction Identification and Extraction in Social Media: A Scoping Review. J Med Internet Res. 2015; 17(7): e171.Lardon J, Abdellaoui R, Bellet F, Asfari H, Souvignet J, Texier N, Jaulent MC, Beyens MN, Burgun A, Bousquet C. Adverse Drug Reaction Identification and Extraction in Social Media: A Scoping Review. J Med Internet Res. 2015; 17(7): e171.

The authors declare that there are no conflicts of interest present.